MA31170B1 - Dérivés de 2-amino-5,7-dihydro-6h-pyrrolo[3,4-d]pyrimidine servant d'inhibiteurs de la hsp-90 pour le traitement du cancer - Google Patents

Dérivés de 2-amino-5,7-dihydro-6h-pyrrolo[3,4-d]pyrimidine servant d'inhibiteurs de la hsp-90 pour le traitement du cancer

Info

Publication number
MA31170B1
MA31170B1 MA32149A MA32149A MA31170B1 MA 31170 B1 MA31170 B1 MA 31170B1 MA 32149 A MA32149 A MA 32149A MA 32149 A MA32149 A MA 32149A MA 31170 B1 MA31170 B1 MA 31170B1
Authority
MA
Morocco
Prior art keywords
hsp
inhibitors
pyrrolo
dihydro
cancer
Prior art date
Application number
MA32149A
Other languages
Arabic (ar)
English (en)
Inventor
Michael John Bennett
Luke Raymond Zehnder
Sacha Ninkovic
Pei-Pei Kung
Jerry Jialun Meng
Buwen Huang
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA31170B1 publication Critical patent/MA31170B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des composés de formule (i) et leurs sels acceptables sur le plan pharmaceutique, leur synthèse et leur utilisation en tant qu'inhibiteurs de la hsp 90.
MA32149A 2007-02-06 2009-08-06 Dérivés de 2-amino-5,7-dihydro-6h-pyrrolo[3,4-d]pyrimidine servant d'inhibiteurs de la hsp-90 pour le traitement du cancer MA31170B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88843307P 2007-02-06 2007-02-06
US2066108P 2008-01-11 2008-01-11
PCT/IB2008/000200 WO2008096218A1 (fr) 2007-02-06 2008-01-25 Dérivés de 2-amino-5,7-dihydro-6h-pyrrolo[3,4-d]pyrimidine en tant qu'inhibiteurs de la hsp 90 pour le traitement du cancer

Publications (1)

Publication Number Publication Date
MA31170B1 true MA31170B1 (fr) 2010-02-01

Family

ID=39367692

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32149A MA31170B1 (fr) 2007-02-06 2009-08-06 Dérivés de 2-amino-5,7-dihydro-6h-pyrrolo[3,4-d]pyrimidine servant d'inhibiteurs de la hsp-90 pour le traitement du cancer

Country Status (22)

Country Link
US (1) US20100093696A1 (fr)
EP (1) EP2118111B1 (fr)
JP (1) JP4523073B2 (fr)
KR (1) KR20090116789A (fr)
AP (1) AP2009004954A0 (fr)
AT (1) ATE502944T1 (fr)
AU (1) AU2008212645A1 (fr)
BR (1) BRPI0807165A2 (fr)
CA (1) CA2677365A1 (fr)
CO (1) CO6220971A2 (fr)
CR (1) CR10963A (fr)
CU (1) CU20090141A7 (fr)
DE (1) DE602008005715D1 (fr)
DO (1) DOP2009000200A (fr)
EA (1) EA200970669A1 (fr)
EC (1) ECSP099565A (fr)
IL (1) IL200169A0 (fr)
MA (1) MA31170B1 (fr)
MX (1) MX2009008386A (fr)
NI (1) NI200900155A (fr)
TN (1) TN2009000329A1 (fr)
WO (1) WO2008096218A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011530580A (ja) * 2008-08-13 2011-12-22 ファイザー・インク 強力なｈｓｐ−９０阻害剤としての２−アミノピリミジン化合物
GB0907284D0 (en) 2009-04-28 2009-06-10 Queen Mary & Westfield College Compounds for inducing cellular apoptosis
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
WO2011082268A2 (fr) 2009-12-30 2011-07-07 Arqule Inc. Composés naphthalényl-pyrimidine substitués
EP2752201A1 (fr) 2013-01-04 2014-07-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibiteurs de HSP90 C-terminal pour traiter les adénomes hypophysaires
US9447025B2 (en) 2013-03-14 2016-09-20 Kalyra Pharmaceuticals, Inc. Bicyclic analgesic compounds
EP3080072A4 (fr) 2013-12-12 2017-07-19 Kalyra Pharmaceuticals, inc. Composés d'alkyle bicyclique et synthèse
CN113336653A (zh) 2014-03-07 2021-09-03 里科瑞尔姆Ip控股有限责任公司 螺桨烷衍生物及合成
CA2952230C (fr) * 2014-06-13 2023-03-21 Yuma Therapeutics, Inc. Composes pyrimidiques et procedes les utilisant
CN106999451B (zh) 2014-09-17 2021-04-02 里科瑞尔姆Ip控股有限责任公司 双环化合物
US10227029B2 (en) * 2015-08-07 2019-03-12 Kawasaki Jukogyo Kabushiki Kaisha Container holder attached to utility vehicle
KR20200018440A (ko) 2017-05-15 2020-02-19 리커리엄 아이피 홀딩스, 엘엘씨 진통제 화합물
WO2020243457A1 (fr) * 2019-05-29 2020-12-03 Viogen Biosciences, Llc Composés et leurs utilisations thérapeutiques

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
AR034118A1 (es) 2000-02-15 2004-02-04 Sugen Inc Compuestos de 2-indolinonas sustituidas con pirroles inhibidoras de proteinquinasas; sus composiciones farmaceuticas e intermediarios de sintesis
US6924290B2 (en) * 2002-01-23 2005-08-02 Bayer Pharmaceuticals Corporation Rho-kinase inhibitors
US7312330B2 (en) * 2003-12-24 2007-12-25 Renovis, Inc. Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
BRPI0609509A2 (pt) * 2005-03-30 2010-04-13 Conforma Therapeutics Corp composto ou um polimorfo, solvato, tautÈmero, enanciÈmero, pró-droga ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso do composto, polimorfo, solvato, tautÈmero, enanciÈmero, pró-droga ou sal farmaceuticamente aceitável

Also Published As

Publication number Publication date
JP4523073B2 (ja) 2010-08-11
TN2009000329A1 (fr) 2010-12-31
CO6220971A2 (es) 2010-11-19
AU2008212645A1 (en) 2008-08-14
WO2008096218A1 (fr) 2008-08-14
CR10963A (es) 2009-08-27
BRPI0807165A2 (pt) 2014-05-06
NI200900155A (es) 2010-06-30
IL200169A0 (en) 2010-04-15
AP2009004954A0 (en) 2009-08-31
EA200970669A1 (ru) 2010-02-26
EP2118111A1 (fr) 2009-11-18
DOP2009000200A (es) 2009-09-15
EP2118111B1 (fr) 2011-03-23
JP2010518066A (ja) 2010-05-27
ECSP099565A (es) 2009-09-29
KR20090116789A (ko) 2009-11-11
US20100093696A1 (en) 2010-04-15
ATE502944T1 (de) 2011-04-15
CU20090141A7 (es) 2011-04-26
CA2677365A1 (fr) 2008-08-14
DE602008005715D1 (de) 2011-05-05
MX2009008386A (es) 2009-10-16

Similar Documents

Publication Publication Date Title
TN2009000329A1 (fr) DERIVES DE 2-AMINO-5,7-DIHYDRO-6H-PYRROLO[3,4-d]-PYRIMIDINE SERVANT D'INHBITEURS DE HSP-90 POUR LE TRAITEMENT DU CANCER
MA31574B1 (fr) Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf
MA31419B1 (fr) Derives de pyridine
MA30709B1 (fr) Derives de pyrido (2, 3-d) pyrimidinone et leur utilisation comme inhibiteurs de pi3.
MA30652B1 (fr) Composes organiques
MA29926B1 (fr) Derives de pyrazine
DK1678166T3 (da) Proteinkinaseinhibitorer
MA37142A3 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
MA31903B1 (fr) Derives de thiazole utilises comme inhibiteur de la pi 3 kinase
MA32965B1 (fr) Derives de sulfonamides
MA30952B1 (fr) Cyclopenta [d] pyrimidines utiles en tant qu'inhibiteurs de la proteine kinase akt
MA31655B1 (fr) Pyrimidines cyclopenta [d] hydroxylés et méthoxylés utilisés en tant qu'inhibiteurs de la protéine kinase akt.
TNSN07022A1 (fr) Derives de pyridine
MA30053B1 (fr) Derives [4-(benzo[b]thiophen-2-yl)-pyrimidin -2-yl]-amine en tant qu'inhibiteurs de ikk-beta pour le traitement du cancer et de maladies inflammatoires .
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
TN2014000115A1 (fr) Derives de pyrrolopyrimidines et de purines
MA38138A1 (fr) Dérivés inédits de quinolone
MA38080A1 (fr) Dérivés substitués de phtalazin-1(2h)-one comme inhibiteurs sélectifs de la poly(adp-ribose) polymérase-1
MA34644B1 (fr) Dérivés de pyrazole aminopyrimidine en tant que modulateurs du lrrk2
MA32135B1 (fr) Inhibiteurs de pim kinase et leurs procedes d'utilisation
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
MA37891B1 (fr) Alcoxypyrazoles comme activateurs de guanylate cyclase soluble
MA29377B1 (fr) Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif
TN2016000188A1 (fr) Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs.
MA35128B1 (fr) Nouveaux dérivés d'imidazole utiles pour le traitement de l'arthrite